![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, August 20, 2013 7:49:33 AM
State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 460,973,956 common shares as of August 12, 2013 .
What is wrong with my math? Since ~$18 billion total market for PD, TBI, Heart Attack, LymPro Diagnostics, Alz, and retina app, and if we assume 10% royalty for licensing MANF and LymPro, and if we assume 460 000 000 shares, and if we assume a conservative PPS multiplier of 1 times revenue, with no taxes, then
Price Per One Share of AMBS is $1,800,000,000 / 460,000,000 = $3.91
....Even if we assume a tax rate of 50% then PPS = $1.96
I guess i will add more today, and wait for these realistic developments! I can wait till at least Dec 2013.
The above does not include any further orphan indications (though more are expected in couple of weeks via Rubin) and more app discoveries from PhenoGuard's 88 celllines. Nor does it take into account NuroPro and BC-SeraPro diagnostics.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM